Recent Posts
- FDA Okays Blood Test for Ovarian Cancer
- Replication At DNA Damage Sites Highlights Fanconi Anemia And Breast Cancer Proteins
- ASCO To Hold Annual Meeting In Chicago For The Next Ten Years: City Seen As Best Choice To Host Meeting That Continues To Grow
- Protein Partnership Leads To Pediatric Tumor Regression
- ASCO Awarded CEO Cancer Gold Standard: Achievement Underscores Organization’s Commitment To The Health And Well-Being Of Its Employees
Random Posts
- FDA Panel Backs Denosumab for Osteoporosis, But Not Osteopenia
- Childhood Cancer Cases And Common Household Pesticides Linked In Washington Area
- Urinary Tract Cancer Associated With Chinese Herbal Products Containing Aristolochic Acid
- ASCO Study Finds Varying Interpretation Of HIPAA Privacy Rule Can Delay Cancer Research
- Tanning Beds Cited as High Cancer Risk
- ASCO Breast: Preop Lymph Node Ultrasound Prevents Second Surgeries (CME/CE)
- Scott And White Healthcare Researcher Finds Success With New Anti-Cancer Drug
- Sound Waves Treat Prostate Cancer With Fewer Side Effects
- Protein Inhibitor Helps Rid Brain Of Toxic Tau Protein
- CytRx's INNO-206 Significantly Inhibits Pancreatic Cancer Growth In Animal Trials
Prescription Cancer Drugs
A New Explanation Of ‘Asian Paradox’
Posted by: admin in Prescription Cancer Drugs on November 08th, 2009
Although Helicobacter pylori (H. pylori) has been classified as a class I (or definite) carcinogen by World Health Organization (WHO), the controversy as to why only a minority of infected patients develop gastric cancer still remains. Moreover, in Asian countries such as Indonesia, Japan, China, and Thailand, where the H. pylori infection rates are similar, there is a significant difference regarding the outcome of gastric cancer. That fact has been termed the “Asian paradox”.
A research article published in the World Journal of Gastroenterology addresses this question. Research, led by Murdani Abdullah, MD from Division of Gastroenterology, Department of Internal Medicine, University of Indonesia, was based on the old concept of a cascade of mucosal changes that develops from acute/chronic gastritis to gastric cancer as proposed by P. Correa. The difference in the pattern of H. pylori-associated gastritis may explain the difference in the incidence of gastric cancer between Indonesia and Japan. Previous studies have never evaluated the cascade of gastric mucosal changes prior to gastric cancer. In this research, the transformation of gastric mucosa that is induced by H. pylori infection prior to gastric cancer was investigated. The transformation was then compared between Indonesian and Japanese patients, the two countries that represent the “Asian paradox”.
From 1998 to 1999, 42 Japanese patients at Yamanashi Medical University Hospital, Koufu and 125 Indonesian patients at Metropolitan Medical Centre Hospital, Jakarta were consecutively enrolled. From this research, it was seen that there was a significant difference in the grade and activity of gastric mucosal changes between Indonesian and Japanese H. pylori-positive patients. This finding suggests that there may be a different host response between Indonesian and Japanese people regarding H. pylori infection. The authors believe that lifestyle and genetic factors are considered to play a major role, in the meantime, their research may act as the initial step in explaining the “Asian paradox”.
Reference: Abdullah M, Ohtsuka H, Rani AA, Sato T, Syam AF, Fujino MA. Helicobacter pylori infection and gastropathy: A comparison between Indonesian and Japanese patients. World J Gastroenterol 2009; 15(39): 4928-4931 http://www.wjgnet.com/1007-9327/15/4928.asp
Source: Jin-Lei Wang
World Journal of Gastroenterology